Collaboration covers proposed trastuzumab biosimilar in Phase III development for human epidermal growth factor receptor 2 positive (HER2+) breast and gastric tumors
Per licence agreement, EirGenix, Inc is responsible for development and manufacturing; Sandoz has right to commercialize in all markets except China and Taiwan
Agreement is third announced biosimilars collaboration for Sandoz in 18 months; will build on robust portfolio of eight approved molecules, with a further 10-plus in development
http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00https://www.sandoz.com/rss/feeds/news/media-releases.xmlhttp://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pnghttps://www.sandoz.com/rss/feeds/news/media-releases.xml2019-04-30 02:00:002019-04-30 02:00:00Sandoz enters agreement for proposed trastuzumab biosimilar, currently in Phase III development, to treat selected HER2-positive cancer tumors
Collaboration covers proposed trastuzumab biosimilar in Phase III development for human epidermal growth factor receptor 2 positive (HER2+) breast and gastric tumors
Per licence agreement, EirGenix, Inc is responsible for development and manufacturing; Sandoz has right to commercialize in all markets except China and Taiwan
Agreement is third announced biosimilars collaboration for Sandoz in 18 months; will build on robust portfolio of eight approved molecules, with a further 10-plus in development
http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00https://www.sandoz.com/rss/feeds/news/media-releases.xmlhttp://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pnghttps://www.sandoz.com/rss/feeds/news/media-releases.xml2019-04-30 02:00:002019-04-30 02:00:00Sandoz enters agreement for proposed trastuzumab biosimilar, currently in Phase III development, to treat selected HER2-positive cancer tumors
